Subject Area and Research Team: V. Cancer imaging

Subject Area and Research Team: V. Cancer imaging


Research topics

1. Assessment of metabolic tumour volume as a predictor of response to treatment in lymphomas

2. Second-generation ultrasound contrast agents as an additional element in the diagnosis and monitoring of treatment response and side effects in paediatric malignancies

3. Diffusion-dependent imaging models, including IVIM (intravoxel incoherent motion) and DKI (diffusion kurtosis imaging) in MRI assessment of large salivary gland tumours

4. Clinical usefulness of quantitative functional MRI parameters in detection, grading and staging of prostate cancer

5.Virtual reality (VR) and augmented reality (AR) in surgery

Coordinators

Coordinator #1 Coordinator #2
Name and surname
K._Markiet.jpg
Karolina Markiet
dr_Bobowicz.jpg
Maciej Bobowicz
Academic degree Ph.D. Ph.D.
Employment unit 2nd Department of Radiology 2nd Department of Radiology
Polish Platform of Medical Research Karolina Markiet, Ph.D. Maciej Bobowicz, Ph.D.
Email karolina.markiet@gumed.edu.pl maciej.bobowicz@gumed.edu.pl
Phone number +48 58 349 36 80 +48 58 349 36 80

photo Paweł Sudara/MUG


Research Team: V. Cancer imaging

Team Members: V. Cancer imaging (280 KB)


Feel free to contact one of our coordinators to join our Research Team.

Key current projects

1. The role of metabolic tumour volume in patients with early stage Hodgkin lymphoma

2. Evaluation of the cut-off values of IVIM and DKI parameters, that alone and/or in combination with ADC value would increase the diagnostic performance of magnetic resonance of parotid glands

3. Evaluation of the concept of diagnostic imaging algorithm in parotid gland tumours without ad-ministration of contrast medium

4. Value of different models of diffusion imaging (standard monoexponential, stretched exponen-tial, diffusion kurtosis imaging) in detection and grading of prostate cancer

5. Project „CLEARLY – Validation of multiparametric models and circulating and imaging biomarkers to improve lung cancer early detection as a part of „Horizon 2020 – the Framework Programme for Research and Innovation (2014-2020) – ERANET on Translational Cancer Research TRANSCAN-2”. Grant no. ERA-NET TRANSCAN/01/2019

Key grants

Funding agency/grant number Title of the project Years
1. Medical Research Agency/ RAFTING-2019/ 2019/ABM/01/00060 RAFT-ING-2019 Radiation-Free Therapy for the Initial treat-ment of good prognosis early non-bulky HL, defined by a low Metabolic Tumour Volume and a negative interim PET after 2 chemo-therapy cycles (RAFTING-2019). 2020-ongoing
2. Siemens /GUMed/x/1176/08/2019/323 Prostate AI prototype 2019-ongoing
3. Horizon 2020 – the Framework Programme for Research and Innovation (2014-2020) – ERA-NET on Translational Cancer Research TRANSCAN-2. Grant no. ERA-NET TRANS-CAN/01/2019 CLEARLY – Validation of multiparametric models and circulating and imaging bi-omarkers to improve lung cancer early de-tection 2018-2020

International cooperation

Foreign partner (unit name) Principal investigator(s) Area of cooperation
1. Sapienza, University of Rome Luciano De Sio Study on the possibility of applying nanoparticles of gold in medicine
2. University of Siena Franco Roviello Molecular analysis, VR and AR collaboration
3. Haematology Research and Innovation Department. A. Lacassagne Cancer Centre – Nice, France Andrea Gallaminii Research on Hodgkin Lymphoma
4. International Association for the Study of Lung Cancer (IASLC), Lung Cancer Screen-ing Committee & ELIC Pro-ject, Denver Colorado Jim Mulshine, Murry Wynes, Ugo Pastorino Diagnostics and treatment of early lung cancer, lung cancer screening
POB_1__RT_5.png


Key publications

1. Sidhu Paul S., Cantisani Vito, Deganello Annamaria, Dietrich Christoph F., Duran Carmina, Franke Doris, Harkanyi Zoltan, KOSIAK WOJCIECH, Miele Vittorio, Ntoulia Aikaterini, PISKUNOWICZ MACIEJ, Sellars Maria E., Gilja Odd Helge. Role of contrast-enhanced ultra-sound (CEUS) in paediatric practice: an EFSUMB position statement. Ultraschall Med. 2017; vol. 389: p. 33-43.

2. Mikaszewski B, Markiet K, Smugała A, Stodulski D, Szurowska E, Stankiewicz 4. Diffusion-weighted MRI in the differential diagnosis of parotid malignancies and pleomorphic ade-nomas: can the accuracy of dynamic MRI be enhanced? Oral Surg Oral Med Oral Pathol Oral Radiol. 2017; vol. 124: p. 95-103.

3. Rzyman W, Szurowska E, Adamek M. Implementation of lung cancer screening at the na-tional level: Polish example. Transl Lung Cancer Res 2019; vol. 8: p. 95-105.

4. Nowicki TK, Markiet K, Izycka-Swieszewska E, Dziadziuszko K, Studniarek M, Szurowska E. Efficacy comparison of multi-phase CT and hepatotropic contrast-enhanced MRI in the dif-ferential diagnosis of focal nodular hyperplasia: a prospective cohort study. BMC Gastroen-terol. 2018; vol. 18: p. 10.

5. Zaucha JM, Malkowski B, Chauvie S, Subocz E, Tajer J, Kulikowski W ,Fijolek-Warszewska A, Biggi A, Fallanca F, Kobylecka M, Dziuk M, Woszczyk D , Rybka J, Kroll-Balcerzak R, Bergesio F, Romanowicz A, Chamier-Cieminska A, Kurczab P, Giza A, Lesniewski-Kmak K, Zaucha R, Swietlik D, Wróbel T, Knopinska-Posluszny W , Walewski J, Gallamini A. The predictive role of interim PET after the first chemotherapy cycle and sequential evaluation of response to ABVD in Hodgkin’s lymphoma patients-the Polish Lymphoma Research Group (PLRG) Observational Study. Ann Oncol. 2017; vol. 28: p. 3051-3057.